Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ABC
ABC logo

ABC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Events Timeline

(ET)
2024-10-17
17:15:07
AmerisourceBergen awarded $2.03B Defense Logistics Agency contract modification
select

News

CNBC
8.5
03-18CNBC
Jim Cramer's Trust Increases Stake in Cardinal Health
  • Increased Stake: Jim Cramer's Charitable Trust purchased 50 shares of Cardinal Health (CAH) at approximately $214 each on Wednesday, raising its total holdings to 450 shares and increasing the portfolio weighting from 2.27% to 2.55%, reflecting confidence in the company.
  • Market Reaction: Since the onset of the Middle East conflict, energy prices and stocks have shown an inverse relationship, with rising oil prices leading to stock sell-offs and concerns about inflation, as evidenced by the S&P 500's decline of over 0.5%.
  • Financial Outlook: Cardinal Health generates nearly 100% of its revenue in the U.S., and management indicated that the recent commodity price spike will have an immaterial impact on its fiscal year 2026 earnings, showcasing its resilience and prompting investors to accumulate shares during market weakness.
  • Industry Dynamics: Despite the healthcare sector's poor performance this month and the retirement of two CFOs raising concerns, Cencora's reaffirmation of its financial guidance has alleviated fears of an impending shortfall, indicating stability within the industry.
CNBC
8.5
03-05CNBC
Analysis of Increased Stake in Cardinal Health
  • Increased Stake: We purchased 90 shares of Cardinal Health at approximately $217, raising our total holdings to 350 shares and increasing its weight from 1.46% to about 2%, demonstrating confidence in the company's future growth potential.
  • Market Performance Analysis: Despite the healthcare sector's poor performance this week, Cardinal Health's stock drop is not tied to fundamentals, providing more upside to our $260 price target, reflecting a misunderstanding of the stock by the market.
  • Industry Dynamics: The drug distribution sector is under pressure, particularly McKesson, which saw a 5% drop in shares following the announcement of its longtime CFO's retirement, indicating market sensitivity to leadership changes, even though this transition was planned.
  • Investment Strategy: We are leveraging our ample cash position to increase our stake in Cardinal Health, replacing our exit from Danaher, which has fallen about 3% since last week, showcasing our ability to flexibly adjust our portfolio amid market fluctuations.
CNBC
8.5
03-02CNBC
Investment Analysis of Cardinal Health
  • New Investment Move: Shortly after the opening bell, Jim Cramer's Charitable Trust will purchase 170 shares of Cardinal Health at approximately $229, resulting in a 1% ownership stake, reflecting confidence in the company's prospects.
  • Market Reaction: Stocks are expected to open sharply lower on Monday due to weekend strikes in Iran, with crude oil prices climbing above $70, heightening concerns about geopolitical risks and inflation, which complicates the market landscape.
  • Long-Term Growth Potential: Cardinal Health plays a crucial role in the U.S. healthcare sector, generating 99% of its revenue domestically, and the ongoing increase in the aging population in the U.S. is expected to provide significant long-term growth tailwinds over the next three decades.
  • Profitability Enhancement: Despite market volatility, Cardinal Health's stock has risen over 70% in the past 12 months and approximately 10% year-to-date, trading at a price-to-earnings ratio of 21 times, indicating strong potential for sustained double-digit earnings growth.
CNBC
6.5
02-27CNBC
Cardinal Health Added to Watchlist
  • Strong Industry Position: Cardinal Health serves as a backbone of the U.S. healthcare industry, supplying and distributing medicines and medical products to hospitals, retail pharmacies, and clinics, thereby ensuring its core role in the healthcare supply chain.
  • Demographic Tailwind: With the continuous increase in the U.S. population aged 65 and over, Cardinal Health is expected to benefit from this long-term trend, as over 50% of this age group takes four or more medications, driving business growth.
  • Market Reaction: Although shares sold off sharply on February 12 due to a logistics company announcing a new tool, the market quickly recognized the overreaction, and the stock rebounded swiftly, demonstrating its economic resilience.
  • Attractive Valuation: Despite Cardinal Health's stock gaining about 10% over the past 12 months, it trades at just 21 times 2026 earnings estimates, which remains attractive relative to its historical levels, reflecting its potential for sustained double-digit earnings per share growth.
CNBC
6.0
01-29CNBC
Wall Street's Latest Ratings and Price Target Adjustments
  • IBM Rating Reaffirmed: Bank of America raised IBM's price target from $335 to $340, driven by strong performance in infrastructure, transaction processing, and data growth, indicating the company's sustained competitiveness in the tech sector.
  • Meta's Strong Performance: Bank of America reiterated its buy rating on Meta, citing a robust Q4 beat and a notably stronger Q1 outlook, highlighting the company's strong growth potential in the social media market.
  • Tesla Competitive Risks: BMO downgraded First Solar to market perform due to competitive pressures from Tesla, particularly as the latter rapidly scales clean energy manufacturing capacity, which may impact First Solar's market positioning.
  • Disney's Attractiveness: Deutsche Bank reiterated its buy rating on Disney, believing the current P/E multiple is at a historical trough, combined with a healthy multi-year earnings growth outlook, making it an attractive investment opportunity.
CNBC
8.5
01-18CNBC
JPMorgan Conference Highlights GLP-1 Drug Market Potential
  • GLP-1 Drug Outlook: Insights from the 44th JPMorgan Healthcare Conference indicate that GLP-1 drugs are poised to become the largest drug class in history, potentially generating billions in revenue for pharmaceutical companies.
  • High Conference Attendance: The conference saw unprecedented participation from pharmaceutical companies, with crowded venues reflecting strong investor interest and demand for new drug developments, significantly higher than in the past decade.
  • Regulatory Impact: The Biden administration's FTC has tightened regulations on Big Pharma's acquisitions of smaller firms, leading to decreased investment activity in the sector and negatively affecting stock performance for companies like Danaher.
  • Competitive Landscape: Eli Lilly's leading position in the GLP-1 market is expected to capture significant market share, with its oral formulation anticipated to receive approval this spring, further solidifying its competitive advantage.
Wall Street analysts forecast ABC stock price to rise
0 Analyst Rating
Wall Street analysts forecast ABC stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
B of A Securities
Michael Funk
Hold
Maintains
$270 → $285
AI Analysis
2025-04-11
Reason
B of A Securities
Michael Funk
Price Target
$270 → $285
AI Analysis
2025-04-11
Maintains
Hold
Reason

Valuation Metrics

The current forward P/E ratio for AMERISOURCEBERGEN CORP (ABC.N) is --, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess AMERISOURCEBERGEN CORP's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
Current PE
NaN
Overvalued PE
Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
Current EV/EBITDA
NaN
Overvalued EV/EBITDA
Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
Current PS
NaN
Overvalued PS
Undervalued PS

Financials

AI Analysis
Annual
Quarterly

Whales Holding ABC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is AMERISOURCEBERGEN CORP (ABC) stock price today?

The current price of ABC is 0 USD — it has increased 0

What is AMERISOURCEBERGEN CORP (ABC)'s business?

What is the price predicton of ABC Stock?

Wall Street analysts forecast ABC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is AMERISOURCEBERGEN CORP (ABC)'s revenue for the last quarter?

AMERISOURCEBERGEN CORP revenue for the last quarter amounts to NaN USD, decreased

What is AMERISOURCEBERGEN CORP (ABC)'s earnings per share (EPS) for the last quarter?

AMERISOURCEBERGEN CORP. EPS for the last quarter amounts to USD, decreased

How many employees does AMERISOURCEBERGEN CORP (ABC). have?

AMERISOURCEBERGEN CORP (ABC) has 0 emplpoyees as of March 25 2026.

What is AMERISOURCEBERGEN CORP (ABC) market cap?

Today ABC has the market capitalization of 0.00 USD.